{"id":"W2590061441","doi":"10.1200/jco.2016.34.2_suppl.200","title":"Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Leuprorelin; Prostate cancer; Clinical endpoint; Urology; Gonadotropin-releasing hormone antagonist; Internal medicine; Interim analysis; Hormone antagonist; Prostate-specific antigen; Testosterone (patch); Prostate; Pharmacokinetics; Antagonist; Gastroenterology; Cancer; Randomized controlled trial; Gonadotropin-releasing hormone; Hormone; Luteinizing hormone; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003895839,0.001525003,0.002278173,0.0003789362,0.0004282532,0.001092396,0.0005991825,0.0008718814,0.01065791],"category_scores_gemma":[0.002973785,0.000446192,0.002360798,0.0002956102,0.0004005746,0.0008108523,0.0005387553,0.002208931,0.001489721],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005520678,"about_ca_system_score_gemma":0.001217306,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002454167,"about_ca_topic_score_gemma":0.0005408969,"domain_scores_codex":[0.9987012,0.0007036137,0.0001110906,0.0001781901,0.0001202476,0.0001856915],"domain_scores_gemma":[0.9984754,0.0004260092,0.0003930601,0.0001928363,0.0001323943,0.0003804053],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9428518,0.008175977,0.003900151,0.0006637716,0.001777219,0.0001423372,0.00006430033,0.0009757379,0.006774242,0.0001552588,0.006334052,0.02818519],"study_design_scores_gemma":[0.6672914,0.2910206,0.02495378,0.00006382183,0.002368764,0.0002994839,0.00003848426,0.001530801,0.003931207,0.0004671201,0.007990891,0.00004347293],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9302946,0.004790541,0.006260362,0.001443025,0.001054146,0.01852441,0.02297454,0.0006372286,0.01402112],"genre_scores_gemma":[0.9399123,0.00105888,0.005947465,0.002074173,0.0005018425,0.02145018,0.01918915,0.0001432741,0.009722836],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01065791,"threshold_uncertainty_score":0.03565425,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1804699472172132,"score_gpt":0.5432057560749756,"score_spread":0.3627358088577624,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}